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BACKGROUND: Venous thromboembolism (VTE) frequently complicates cancer. Data on tumour-specific VTE predictors are limited,
but may inform strategies to prevent thrombosis.
METHODS: We computed incidence rates (IRs) with 95% confidence intervals (CIs) for VTE hospitalisation in a cohort of cancer
patients (n¼57591) and in a comparison general-population cohort (n¼287476) in Denmark. The subjects entered the study in
1997–2005, and the follow-up continued through 2006. Using Cox proportional-hazards regression, we estimated relative risks
(RRs) for VTE predictors, while adjusting for comorbidity.
RESULTS: Throughout the follow-up, VTE IR was higher among the cancer patients (IR¼8.0, 95% CI¼7.6–8.5) than the general
population (IR¼4.7, 95% CI¼4.3–5.1), particularly in the first year after cancer diagnosis (IR¼15.0, 95% CI¼13.8–16.2, vs IR¼8.6,
95% CI¼7.6–9.9). Incidence rates of VTE were highest in patients with pancreas (IR¼40.9, 95% CI¼29.5–56.7), brain (IR¼17.7, 95%
CI¼11.3–27.8) or liver (IR¼20.4, 95% CI¼9.2–45.3) tumours, multiple myeloma (IR¼22.6, 95% CI¼15.4–33.2) and among
patients with advanced-stage cancers (IR¼27.7, 95% CI¼24.0–32.0) or those who received chemotherapy or no/symptomatic
treatment. The adjusted RR (aRR) for VTE was highest among patients with pancreas (aRR¼16.3, 95% CI¼8.1–32.6) or brain cancer
(aRR¼19.8 95% CI¼7.1–55.2), multiple myeloma (aRR¼46.1, 95% CI¼13.1–162.0) and among patients receiving chemotherapy,
either alone (aRR¼18.5, 95% CI¼11.9–28.7) or in combination treatments (aRR¼16.2, 95% CI¼12.0–21.7).
CONCLUSIONS: Risk of VTE is higher among cancer patients than in the general population. Predictors of VTE include recency of cancer
diagnosis, cancer site, stage and the type of cancer-directed treatment.
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Since Trousseau’s observation in 1865 (Trousseau, 1865), venous
thromboembolism (VTE) has been widely documented as a serious
complication of malignancy (Rickles and Levine, 2001; Prandoni
et al, 2005; Blom et al, 2006b). Factors implicated include tumour-
induced hypercoagulability; vascular injury caused by tumour,
treatment or surgery; and, among bed-ridden cancer patients,
venous stasis due to immobilisation (Gouin-Thibault et al, 2001;
Prandoni et al, 2005; Zwicker et al, 2009).
The identification of factors associated with the incidence and
clinical time-course of VTE in cancer patients compared with the
general population is fundamental for further understanding of
the association between cancer and VTE, and potentially prevent
the occurrence of VTE. Risk factors for VTE include cancer type
(adenocarcinomas of the viscera, brain and urogenital cancers);
advanced stage; and cancer therapies, such as chemotherapy and
surgery (Otten et al, 2004; Chew et al, 2006; Ogren et al, 2006; Stein
et al, 2006; Khorana et al, 2007; Rodriguez et al, 2007). Although
there is evidence that cancer patients have twice the risk of VTE
compared with non-cancer patients undergoing the same surgical
procedures (Rickles and Levine, 2001), few investigations have
directly compared VTE incidence in cancer patients with cancer-
free members of the general-population (Blom et al, 2006b; Heit
et al, 2001; White et al, 2007). None of the previous studies were
able to implement matching, which, in cohort studies, enables
control of potential confounding at the design stage.
We took advantage of Danish population-based registries to
conduct a study of predictors of VTE, including cancer site, stage,
treatment and time since diagnosis, in cancer patients using a matched
cohort design with prospectively collected data, a task which is
prohibitively expensive in conventional epidemiological settings.
MATERIALS AND METHODS
Study population
We conducted this cohort study among individuals aged
X15 years residing in northern Denmark (1.8 million inhabitants).
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sIn Denmark, all medical records are tracked for individual patients
using their civil personal registration number—a unique identifier
encoding sex and date of birth—assigned to all Danish residents
since 1968. Using the civil personal registration number, we linked
data from the Danish National Registry of Patients (DNRP), the
Danish Cancer Registry (DCR) and the Danish Civil Registration
System (Andersen et al, 1999; Frank, 2000; Pedersen et al, 2006).
The DNRP has tracked acute non-psychiatric hospitalisations
since 1977 and outpatient and emergency-room visits since 1995;
diagnoses have been coded using the eighth revision of the
International Classification of Diseases (ICD-8 (Sundhedsstyrelsen,
1986)) through 1993 and the tenth revision (ICD-10 (Sundheds-
styrelsen, 1993)), thereafter. Information is recorded immediately
after discharge or outpatient visit and includes admission and
discharge dates, and up to 20 diagnoses (Andersen et al, 1999). We
obtained complete hospital history (including VTE) for the cancer
and general-population cohorts and linked the resulting data set to
records in the Civil Registration System, which tracks vital status
and migration nationwide.
Cancer cohort
From the DNRP, we identified individuals in the study area with a
first cancer diagnosis, excluding non-melanoma skin cancer
(ICD-10 codes: C00-C97.9) recorded between January 1, 1997 and
December 31, 2005. We chose this period to ensure homogeneity of
VTE diagnostic procedures (for example, ultrasound for deep vein
thrombosis) for the included cancer patients (Lensing et al, 1989).
The date of cancer diagnosis was that specified in the DNRP.
We eliminated cases (B6%) for which a hospital diagnosis did not
correspond to an incident cancer recorded at the same site in the
DCR. All Danish cancer cases are reportable to the DCR and
recorded using the ICD-7 (seventh revision) since 1943 and ICD-O
(oncology revision) since 1977. The DCR is over 95% complete
and has almost 100% validity (Storm et al, 1997). For cancers
diagnosed in 2004–2005, we included patients with cancers
recorded in the DNRP only because DCR records were not
available for this period.
Because VTE can indicate undiagnosed cancer (Baron et al,
1998; Sorensen et al, 1998), we excluded cancer patients diagnosed
with VTE in the year before their cancer diagnosis (n¼124) from
all analyses.
General-population cohort
We used the Civil Registration System to assemble a general-
population comparison cohort (Frank, 2000). For each patient with
cancer, we randomly selected five general-population members
from a pool of individuals who were alive and free of cancer on the
date of the matched person’s cancer diagnosis as recorded in the
DNRP (the index date), matched on birth year, sex and county of
residence.
To maintain comparability of the cohorts, we also excluded from
the pool of the general-population members available for matching
persons who had been diagnosed with VTE in the year before the
index date.
Tumour predictors of VTE
In sub-analyses limited to cancer patients and their matched
comparison group diagnosed while DCR records were available
(o2004), we ascertained information on cancer site from the DCR.
The DCR records data on cancer stage and treatment administered
within 4 months of diagnosis (initial treatment). We classified
cancer stage according to Tumour Node Metastasis stages I, II, III,
IV and unknown. To examine VTE incidence by treatment and
stage, we conducted a sub-analysis, including patients with records
in the DCR and DNRP through 2003 and their matched members
of the general-population, yielding a 6-year maximum follow-up.
Comorbidity data
We used the DNRP to retrieve information on history of inpatient
diagnoses of potential confounding diseases. We ascertained
the following diagnoses: myocardial infarction (ICD-8:410;
ICD-10:I21), congestive heart failure (ICD-8:427; ICD-10:I50.0),
atherosclerosis and peripheral vascular disease (ICD-8:440; ICD-
10:I73), chronic obstructive pulmonary disease (ICD-8:491;
ICD-10:J44), inflammatory bowel disease (ICD-8:563; ICD-
10:K50–K52), peptic ulcer disease (ICD-8:531–533; ICD-10:K27),
liver disease (ICD-8:570–573; ICD-10:K70–K77), renal disease
(ICD-8:400–404; ICD-10:I10–I15), diabetes (ICD-8:249 and 250;
ICD-10:E10–E14), obesity (ICD-8:277; ICD-10:E66), pancreatitis
(ICD-8:577.00–577.09; ICD-10:K85), alcoholism and alcoholism-
related conditions (ICD-8:291–303; ICD-10:F10) and hypertension
(ICD-8:400–404; ICD-10:I10–I15).
VTE data
Individuals were followed-up from the cancer diagnosis/index date
until an inpatient VTE diagnosis, death, emigration or 31
December 2006, whichever came first, or until cancer diagnosis
for members of the general-population cohort, for 9 years
maximum follow-up. We did not include individuals with an
outpatient or emergency-room VTE diagnosis without a subse-
quent inpatient diagnosis, because such diagnoses were likely to
represent coding errors (Severinsen et al, 2010). We used all
diagnosis fields in the DNRP to identify VTE events that occurred
after cancer diagnosis/index date and included pulmonary
embolism (ICD-10: I26), phlebitis and thrombophlebitis (deep
vein thrombosis or superficial thrombosis—ICD-10: I80) and
other venous embolism and thrombosis (ICD-10: I81 and I82).
Statistical analyses
We computed crude incidence rates (IRs) of hospitalisation for
VTE as the number of cases per 1000 person-years (p-y) and
associated 95% confidence intervals (CI) for the cancer and
general-population cohorts. Among the cancer patients, we
estimated VTE incidence by patient, tumour and treatment
characteristics and by time since cancer diagnosis. Incidence rates
were compared using the Poisson distribution; two-sided P-values
o0.05 were considered statistically significant. We compared IRs
of VTE between men and women for cancers that affect both men
and women. To describe time to and absolute risk of VTE, we
constructed Nelson–Aalen plots using product-limit methods
(Ludbrook and Royse, 2008) illustrating cumulative incidence for
VTE in select cancers.
We used Cox proportional-hazards regression to estimate the
hazard ratio as a measure of the relative risk (RR) of VTE among
cancer patients compared with the general-population, adjusting
for comorbidity. For the analysis of time since diagnosis,
additional adjustment for age and sex was done in the regression
model to account for any age and sex imbalances potentially
produced by differences in the cohort composition after the
diagnosis/index date. We examined the RR of ‘provoked’ and
‘unprovoked’ VTE by stratifying our analyses by the receipt
of surgery within 90 days before the VTE diagnosis (Glynn and
Rosner, 2005).
In an analysis restricted to the cancer patients, we also
computed RRs to assess the association between VTE risk and
cancer site, stage and initial treatment, adjusting for age, sex,
county and comorbidity using colon cancer as a reference group.
Cox proportional-hazards regression was also used to examine
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swhether any cancer site-related differences were explainable by
stage and/or treatment.
RESULTS
Descriptive data
We identified 57591 incident cancer cases diagnosed between 1997
and 2005 and matched 287476 individuals without cancer from the
general-population (Table 1). Follow-up spanned 127492 p-y for
the cancer cohort (median: 1.23 p-y) and 1087946 p-y for the
general-population cohort (median: 3.46 p-y). The most common
cancer sites were the colorectum, lung and breast, each represent-
ing approximately 14% of all cancers. There were slightly more
women than men in the study sample (52 versus 48%) and 69% of
the sample were aged at least 60 years at cancer diagnosis/ index
date.
Incidence rate of hospitalisation for VTE
The overall IR of VTE in cancer patients was 8.0 cases per 1000 p-y
(95% CI¼7.6–8.5, Table 2). Incidence was highest during the
first year following cancer diagnosis (15.0 cases per 1000
p-y, 95% CI¼13.8–16.2), declining to 6.3 cases per 1000 p-y
(95% CI¼5.4–7.3) during the second year following cancer
diagnosis and to 4.2 cases per 1000 p-y (95% CI¼3.7–4.7)
thereafter (Supplementary Table 2). For cancers that affect men
and women, the rate of VTE in men (IR¼10.0 cases per 1000 p-y,
95% CI¼9.1–11.0) was very similar to that in women (IR¼10.1
cases per 1,000 p-y, 95% CI¼9.1–11.3), (P¼0.99).
The cumulative incidence of VTE after cancer diagnosis initially
rose sharply, with a diminishing rate of increase over subsequent
years (Figure 1). Overall, during the first year of follow-up,
VTE was diagnosed in 1.4% of cancer patients and in 0.2% of the
general-population cohort, and this difference varied by cancer site
(e.g., 4.4% for pancreas and 0.7% for breast vs 0.3 and 0.1% in the
general-population comparators for these cancers, respectively).
VTE IRs were highest for patients with pancreas, liver, lung, ovary
and brain cancers, and for multiple myeloma (Supplementary
Table 2). Overall, the IRs of VTE were higher in the first year after
the index date than in subsequent years. However, for some
cancer sites (pancreas, liver and lung) the CIs associated with rates
in the first year overlapped with those associated with rates in
subsequent years.
RR of VTE among cancer patients compared with the
general population
Overall, the risk of VTE was higher among cancer patients than in
the general population, after adjustment for comorbid conditions
Table 1 Characteristics of the cancer and general-population cohorts and the distribution of incident hospitalisation for VTE (Danish National Registry of
Patients, 1997–2005)
Cancer patients General-population cohort
Characteristic
Total
number
VTE
number (%)
a
Observation time,
person-years
Total
number
VTE
number (%)
a
Observation time,
person-years
Overall 57591 1023 (1.8%) 127492 287476 2204 (0.8%) 1087946
Sex
Female 30060 527 (1.8%) 74825 150078 1088 (0.7%) 592092
Male 27531 496(1.8%) 52667 137398 1116 (0.8%) 495854
Age at diagnosis, years
o50 7356 105 (1.4%) 24427 36792 82 (0.2%) 158635
50–59 10262 215 (2.1%) 27337 51231 204 (0.4%) 215803
60–69 14231 305 (2.1%) 31885 71143 502 (0.7%) 285230
70–79 16068 271 (1.7%) 30405 80181 882 (1.1%) 291450
80–89 8702 119 (1.4%) 12504 43245 497 (1.1%) 126419
90+ 972 8 (0.8%) 935 4884 37 (0.8%) 10409
Cancer site
Oesophagus 938 14 (1.5%) 872 4682 29 (0.6%) 17155
Stomach 1172 18 (1.5%) 1417 5851 61 (1.0%) 21933
Colon 5595 126 (2.3%) 13252 27922 230 (0.8%) 100694
Rectum 2778 55 (2.0%) 7361 13866 113 (0.8%) 52623
Liver 550 6 (1.1%) 295 2746 11 (0.4%) 10216
Pancreas 1671 36 (2.2%) 881 8342 80 (1.0%) 30467
Lung 7975 127 (1.6%) 7872 39810 336 (0.8%) 151350
Breast 8586 119 (1.4%) 30391 42869 234 (0.5%) 171760
Cervix 1019 16 (1.6%) 3499 5090 24 (0.5%) 22341
Endometrium 1453 22 (1.5%) 5049 7258 59 (0.8%) 28604
Ovary 1534 49 (3.2%) 4066 7663 48 (0.6%) 31828
Prostate 4457 98 (2.2%) 9757 22230 219 (1.0%) 70899
Kidney 1376 12 (0.9%) 2972 6864 37 (0.5%) 25538
Urinary bladder 2445 62 (2.5%) 5980 12205 116 (1.0%) 45436
Brain 1133 19 (1.7%) 1071 5653 37 (0.7%) 21685
Hodgkin lymphoma 336 6 (1.8%) 1143 1680 4 (0.2%) 6851
Non-Hodgkin lymphoma 2003 47 (2.3%) 4788 9999 79 (0.8%) 38013
Leukaemia 1516 41 (2.7%) 2943 7567 66 (0.9%) 28060
Multiple myeloma 643 26 (4.0%) 1149 3211 30 (0.9%) 11972
Bone 229 4 (1.4%) 541 1143 7 (0.6%) 4709
Abbreviation: VTE¼venous thromboembolism.
aVTEs which occurred in the year before cancer diagnosis/ index date were excluded.
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of VTE declined with increasing age at diagnosis, particularly for
events during the first year after cancer diagnosis (aRR¼21.0, 95%
CI¼11.0–39.9 among those aged o50 years vs aRR¼7.0, 95%
CI¼1.7–29.6 among those aged at least 90 years) (P¼0.14)
(Supplementary Table 2). The aRR of VTE varied by cancer site,
with higher RRs for oesophagus, pancreas and brain cancers or
multiple myeloma and lower RRs for breast, endometrial and
kidney cancer. For most cancer sites, the aRRs of VTE were higher
during the first and second years of follow-up than in subsequent
years. Surgery within 90 days of VTE conferred a significantly
increased risk of VTE (see Supplementary Table 5). This was true
for all years of follow-up.
Cancer stage, treatment, site and risk of VTE
Our sub-analysis of patients with cancer records in both the DCR
and DNRP included 40994 cancer patients diagnosed between
1997 and 2003 (comprising 91.3% of cases identified in the DNRP
during this period) and their 204970 matched cancer-free
members of the general-population. The effect of cancer on VTE
risk increased with advancing tumour stage (aRR (95% CI)¼2.9
(1.5–5.5); 2.9 (2.4–3.5); 7.5 (6.0–9.4); and 17.1 (12.6–23.3) among
patients with stage I, II, III and IV disease, respectively, Table 3).
VTE IRs were highest among patients who received initial
treatment of either chemotherapy alone or no/symptomatic
treatment compared with patients treated with any other regimen
or combination therapy (Table 3). After adjusting for comorbidity,
age and sex, relative to the general-population cohort, VTE risk
in cancer patients was strongest in those treated with any
chemotherapy-containing regimen as part of initial cancer
treatment (aRR¼18.5, 95% CI¼11.9–28.7 for chemotherapy
alone and aRR¼16.2, 95% CI¼12.0–21.7 for chemotherapy
combined with other treatments). VTE risk among patients who
received chemotherapy within 4 months of cancer diagnosis
remained substantially elevated during the first 2 years after
cancer diagnosis, whereas it diminished substantially after the first
year among patients treated with radiotherapy or surgery
(Supplementary Table 3).
In the cancer cohort only, we examined the RR of VTE for
tumour site, stage and treatment, while adjusting for sex, age,
county and comorbid conditions. Compared with colon cancer,
VTE risk was higher for brain, liver, ovary and pancreas cancers
and lower for breast cancer and melanoma after controlling
for stage and treatment (Supplementary Table 4). Likewise,
chemotherapy was associated with a higher VTE risk compared
with no/symptomatic treatment. VTE risk increased markedly with
advancing stage.
DISCUSSION
We found that cancer patients had a greater risk for hospitalisation
with VTE (1.8%) than cancer-free members of the general
population (0.8%). The overall incidence of VTE in the cancer
cohort is consistent with that reported in other studies (1.2%
within the first 6 months; 1.6% within the first 2 years and 2.0%
over all years of follow-up after cancer diagnosis (Blom et al,
2006a; Chew et al, 2006; Stein et al, 2006). VTE risk was increased
over eight-fold during the first year following cancer diagnosis,
over three-fold during the second year and over two-fold during
subsequent years. In addition to survival time, strong predictors of
VTE were cancer site, stage and type of initial cancer treatment.
The cancers we found associated with especially high rates of
VTE (pancreas, liver, brain and multiple myeloma) are consistent
with other research (Baron et al, 1998; Levitan et al, 1999; Blom
et al, 2005; Blom et al, 2006b; Chew et al, 2006). Pancreas cancer
has been associated with a high VTE risk (Chew et al, 2006; Ogren
et al, 2006). Although it is frequently metastatic at diagnosis and
may be associated with VTE on that basis alone, it has been
suggested that an unknown VTE risk factor inherent to pancreas
cancer may further increase risk (Ogren et al, 2006).
An important finding of our study is the high VTE risk
associated with multiple myeloma, consistent with some published
findings (Blom et al, 2006b; Khorana et al, 2007). New treatments
for myeloma emerged during the period of our analysis, including
the anti-angiogenic agents thalidomide and lenalidomide (Hales,
1999; Singhal et al, 1999). Recent reports suggest that thrombo-
prophylaxis in myeloma patients may decrease the risk of VTE
associated with these treatments (Knight et al, 2006; Falanga and
Marchetti, 2009).
We confirmed the findings from Keenan and White, who
concluded no evidence of a sex difference in VTE incidence either
during hospitalisation or in the first year following cancer
diagnosis (Keenan and White, 2007). Similar to our findings,
studies show a decline in the overall IR of VTE in cancer patients
with longer follow-up (Blom et al, 2005; Chew et al, 2006; White
et al, 2007). Despite this, the excess risk of VTE in the cancer
Table 2 IRs of hospitalisation for VTE per 1000 person-years in the
cancer cohort
Characteristic IR (95% CI) aRR (95% CI)
Overall 8.0 (7.6–8.5) 4.7 (4.3–5.1)
Sex
Female 7.0 (6.5–7.7) 4.8 (4.2–5.4)
Male 9.4 (8.6–10.3) 4.6 (4.1–5.3)
Age, years
o50 4.3 (3.6–5.2) 8.7 (6.2–12.2)
50–59 7.9 (6.9–9.0) 9.6 (7.6–12.2)
60–69 9.6 (8.6–10.7) 5.6 (4.7–6.6)
70–79 8.9 (7.9–10.0) 3.1 (2.7–3.7)
80–89 9.5 (8.0–11.4) 2.9 (2.3–3.7)
90+ 8.6 (4.2–17.1) 3.0 (1.1–8.7)
Cancer site
Oesophagus 16.1 (9.5–27.1) 11.6 (3.8–35.0)
Stomach 12.7 (8.0–20.2) 8.9 (3.8–20.7)
Colon 9.5 (8.0–11.3) 4.8 (3.7–6.2)
Rectum 7.5 (5.7–9.7) 4.0 (2.8–5.9)
Liver 20.4 (9.2–45.3) —
a
Pancreas 40.9 (29.5–56.7) 16.3 (8.1–32.6)
Lung 16.1 (13.6–19.2) 8.0 (6.0–10.7)
Breast 3.9 (3.3–4.7) 3.3 (2.6–4.2)
Cervix 4.6 (2.8–7.5) 10.8 (4.2–28.1)
Endometrium 4.4 (2.9–6.6) 2.2 (1.1–3.9)
Ovary 12.1 (9.1–15.9) 10.1 (6.1–16.7)
Prostate 10.0 (8.2–12.2) 3.1 (2.4–4.1)
Kidney 4.0 (2.3–7.1) 2.7 (1.1–6.6)
Urinary bladder 10.4 (8.1–13.3) 4.5 (3.1–6.4)
Brain 17.7 (11.3–27.8) 19.8 (7.1–55.2)
Hodgkin Lymphoma 5.3 (2.4–11.7) 9.7 (2.3–41.3)
Non-Hodgkin Lymphoma 9.8 (7.4–13.1) 6.6 (4.2–10.5)
Leukaemia 13.9 (10.3–18.9) 9.1 (5.3–15.8)
Multiple Myeloma 22.6 (15.4–33.22) 46.1 (13.1–162.0)
Bone 7.4 (2.8–19.7) 9.7 (0.7–130.9)
Abbreviations: aRR¼adjusted relative risk; CI¼confidence interval; IR¼incidence
rate; VTE¼venous thromboembolism. Cox proportional hazards regression models
computing the adjusted relative risks (aRRs) (Adjusted for myocardial infarction,
congestive heart failure, peripheral vascular disease, chronic obstructive pulmonary
disease, inflammatory bowel disease, peptic ulcer disease, liver disease, renal disease,
diabetes, obesity, acute pancreatitis, alcoholism and hypertension when the number
of VTE events for a given comorbidity was sufficient) of hospitalisation for VTE in the
cancer cohort compared with the general-population (Danish National Registry of
Patients, 1997–2005). Please see Supplementary Information for IR and RR by time since
diagnosis/index date.
aToo few VTE events to estimate incidence.
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scohort compared with the general population prevailed throughout
follow-up possibly because of patient, cancer and treatment related
factors. A study of ovarian cancer patients suggested that early
thrombotic events were associated with cancer treatment, whereas
later events correlated with older age, a history of thrombosis,
advanced stage and residual disease (Rodriguez et al, 2007).
The greater overall excess risk of VTE among cancer patients
with advanced stage in our study agrees with other studies (Blom
et al, 2006b; Chew et al, 2006; Rodriguez et al, 2007), and was
evident even after adjusting for cancer site. Furthermore, our
findings clearly showed that chemotherapy is a predictor of VTE in
cancer patients, as has been reported (Otten et al, 2004; Blom et al,
2006b; Khorana et al, 2007). This excess risk was evident even after
adjusting for cancer site and stage.
Regarding surgery, White et al. (2007) reported that patients
surgically treated for cancers of the colon, breast and ovary had the
lowest VTE incidence within 3 months of diagnosis compared with
patients with cancer at other sites, whereas those with gliomas had
the highest incidence in that time period. Although elevated
relative to the general population, in our study the IR associated
with surgery was not as high as that for chemotherapy. However,
surgery is not a treatment option for all cancers (e.g., haemato-
logical cancers or those metastatic at diagnosis). Surgical patients
may also have received post-surgical thromboprophylaxis
(White et al, 2007), may have been selected for better performance
status and overall health status, and/or may have had non-
advanced (thus operable) disease at diagnosis. If true, these factors
would decrease the apparent VTE risk among surgical patients.
Recent surgery is a strong transient risk factor for VTE, denoted
‘provoked VTE’ (Glynn and Rosner, 2005; Huerta et al, 2007).
Our findings regarding such ‘provoked VTE’ concur with those
of Huerta and colleagues (Huerta et al, 2007), who reported a nine-
fold excess risk of VTE among individuals who had surgery up to
6 months before VTE diagnosis.
Strengths of our study include prospectively collected data and
complete follow-up, reducing selection bias. Cancer diagnoses
recorded in the DCR and DNRP have a high validity (Storm, 1988).
We had a large sample size, enabling the study of many cancers,
including rare cancers, such as multiple myeloma. Inability to
examine rare cancers has been a limitation of other, smaller,
studies (Heit et al, 2001; Blom et al, 2005).
Limitations of our study include lack of clinical characteristics
and personal detail regarding the subjects. In particular, our
findings may have been affected by unmeasured confounding by
VTE risk factors, such as post-menopausal hormone replacement
therapy and thromboprophylaxis, which could contribute to
or diminish the observed cancer effect on risk of VTE. We relied
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Figure 1 Cumulative incidence of hospitalisation for venous thromboembolism (VTE) in the cancer and general-population cohorts overall and
for the four most common cancer types (Danish National Registry of Patients, 1997–2005).
Table 3 IRs of hospitalisation for VTE
a per 1000 person-years in the
cancer cohort (n¼40994) and aRRs
b of hospitalisation for venous
thromboembolism in the cancer cohort compared with the general-
population (n¼204970) (DCR, 1997–2003)
c
Characteristic N IR (95% CI) aRR
b (95% CI)
Cancer stage
c
Stage I 1240 44 (2.7–7.1) 2.9 (1.5–5.5)
Stage II 14520 44.9 (4.0–5.7) 2.9 (2.4–3.5)
Stage III 10499 11.1 (9.7–12.7) 7.5 (6.0–9.4)
Stage IV 9125 27.7 (243.0–32.0) 17.1 (12.6–23.3)
Unspecified 5610 12.2 (10.1–14.8) 5.6 (4.1–7.5)
Treatment
c,d
No/symptomatic 8565 20.8 (17.3–25.0) 8.4 (6.2–11.4)
Chemotherapy only 3026 23.1 (19.0–28.1) 18.5 (11.9–28.7)
Radiation only 2512 10.1 (7.2–14.1) 8.9 (5.0–16.0)
Surgery only 16564 6.5 (5.7–7.3) 3.2 (2.7- 3.8)
Other
e 781 13.4 (7.6–23.7) 6.0 (2.3–15.6)
Combination therapy 8625 8.5 (7.3–9.9) 8.6 (6.7–11.1)
Unspecified 921 9.2 (4.8–17.6) 5.8 (2.1–16.6)
Treatment including
c
No/symptomatic 8565 20.8 (17.3–25.0) 8.4 (6.2–11.4)
Chemotherapy 7154 14.0 (12.2–16.2) 16.2 (12.0–21.7)
Radiation 6943 8.2 (6.8–9.9) 7.9 (5.8–10.7)
Surgery 24525 7.0 (6.3–7.7) 4.1 (3.6- 4.7)
Other
e 781 13.4 (7.6–23.7) 6.0 (2.3–15.6)
Unspecified 921 9.2 (4.8–17.6) 5.8 (2.1–16.6)
Abbreviations: aRR¼adjusted relative risk; CI¼confidence interval; DCR¼Danish
Cancer Registry; IR¼incidence rate; VTE¼venous thromboembolism. Please
see Supplementary Information for IR and RR by time since diagnosis/index date.
aWe excluded VTEs that occurred in the year before diagnosis/ index date.
bAdjusted
for age, sex, myocardial infarction, congestive heart failure, peripheral vascular disease,
chronic obstructive pulmonary disease, inflammatory bowel disease, peptic ulcer
disease, liver disease, renal disease, diabetes, obesity, acute pancreatitis, alcoholism
and hypertension when the number of VTE events for a given comorbidity was
sufficient.
cTo obtain data on cancer stage and treatment, analyses are based on
cancer patients in the DCR and their matched members of the general-population
cohort.
dMutually–exclusive treatment categories
eOthers describe treatment
other than chemotherapy, radiation and/or surgery. This includes cryocoagulation,
anti-hormone therapy and other treatments not further specified.
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son recorded registry diagnoses, which are not perfect. VTE
diagnosis in the DNRP has an estimated positive predictive value
of 75% (95% CI¼71.9–77.9%) (Severinsen et al, 2010). Our
outcome variable, VTE, includes upper extremity VTE, which has
no dedicated ICD code (Sundhedsstyrelsen, 1993) and can occur as
a complication of indwelling catheters in cancer patients (Bernardi
et al, 2001). However, most patients have VTE at sites other than
the upper extremities (Arcelus et al, 2003). Our inclusion of
superficial venous thrombosis may have contributed to the
elevated IRs associated with cancer treatment and in the first year
after cancer diagnosis because superficial venous thrombosis may
result from venous catheters associated with chemotherapy or
surgery. Cancer patients may have received heightened surveil-
lance for VTE, leading to surveillance bias and inflating our VTE
RR estimates. Such bias is unlikely to extend beyond 1 year of
follow-up; when most cancer patients receive active treatment and
close medical observation (Rodriguez et al, 2007).
The DCR records treatment administered within 4 months of
diagnosis. Therefore, if a treatment increases VTE risk and is
administered over 4 months after cancer diagnosis, we may have
underestimated its impact. A ‘watchful waiting’ strategy (where
treatment was administered on appearance of symptoms) may
explain the consistently high excess risk of VTE among prostate
cancer patients throughout follow-up, whereas VTE risk associated
with many other cancers declined over time.
Our study furthers the understanding of the association between
cancer and VTE. Within the cancer cohort, the elevated risk of
VTE for some cancer sites, even after adjusting for cancer
treatment, stage, age, sex and potential confounding diseases,
suggests that increased VTE occurrence is an inherent biological
property of some tumours (e.g., brain and pancreas cancers).
In cancers associated with a slightly elevated risk of VTE
compared with the general population (e.g., breast cancer), VTE
may be attributable to cancer-directed treatment or stage (Stein
et al, 2006; Hernandez et al, 2009). VTE may also be related to the
biological aggressiveness of the malignant process in general as
suggested by the elevated risk of VTE in all patients
with advanced stage. However, cancer patients are also likely to
be burdened with increased medical intervention and forced
sedentary lifestyle, factors that would increase the VTE risk.
Nonetheless, in our study, even patients with early-stage cancer
had increased VTE risk relative to the general population. The
increased risk persisted among patients who received treatments
other than chemotherapy or no/symptomatic treatment and
remained elevated throughout follow-up. These findings suggest
that some factors underlying the association between VTE and
cancer are present even at the earliest stages of disease. The likely
multi-factorial mechanism for increased VTE risk in cancer
patients remains to be elucidated (Kakkar, 2010).
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